This also indicates that CRP cannot be utilized as a reliable marker of severe bacterial infection in these patients (20), and in contrast to the GiACTA trial, a multicentre study in patients with GCA given tocilizumab reported far more serious infections (11.9%) (21). The gene discussed is CRP; the disease is infection.